Core Insights - Alto Neuroscience has reported strong financial results for the year 2025, with a cash balance of approximately $177 million, expected to fund operations into 2028 and support four key data readouts in its precision psychiatry pipeline [1][6][9] Business Highlights - The acquisition of ALTO-207, targeting Treatment-Resistant Depression (TRD), is a significant development, with a Phase 2b trial set to begin in the first half of 2026 [1][3] - The PAX-D study published in The Lancet Psychiatry showed a 0.87 effect size for ALTO-207's core mechanism, indicating a significantly larger effect than current standard treatments [1][4] - ALTO-101 has received FDA Fast Track Designation for Cognitive Impairment Associated with Schizophrenia (CIAS), with topline Phase 2 Proof-of-Concept data expected by the end of Q1 2026 [1][5] Financial Performance - Research and development expenses for 2025 were $45.6 million, a decrease from $47.0 million in 2024, primarily due to the completion of previous studies [8] - General and administrative expenses were $20.7 million in 2025, down from $21.6 million in 2024 [9] - The net loss for 2025 was $63.2 million, compared to a net loss of $61.4 million in 2024, with a net loss per share of $2.19 [9][15] Upcoming Milestones - The Phase 2b trial for ALTO-207 is expected to initiate in the first half of 2026, with topline data anticipated in the second half of 2027 [3][6] - ALTO-300 and ALTO-100 are also in ongoing Phase 2b trials, with topline data expected in mid-2026 and the second half of 2026, respectively [7]

Core Viewpoint - Alto Neuroscience is actively participating in various investor conferences and has announced the completion of patient enrollment in a Phase 2 clinical trial for its drug candidate ALTO-101, aimed at treating cognitive impairment associated with schizophrenia [1][1][1] Group 1: Company Announcements - Alto Neuroscience will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, with a live webcast available for investors [1] - The company is also set to participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 PM ET [1] Group 2: Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] Group 3: Research Contributions - A review co-authored by Alto Neuroscience's leadership team has been published in the American Journal of Psychiatry, discussing neuroplasticity as a core driver of psychiatric diseases and potential treatments [1]

Summary of Alto Neuroscience Conference Call Company Overview - **Company**: Alto Neuroscience - **Industry**: Biotechnology, specifically focused on mental health care and psychiatric treatments Core Programs and Focus Areas - **Mission**: Transform mental health care through precision psychiatry, targeting unmet needs in depression and schizophrenia [3][4] - **Key Programs**: - **ALTO-207**: A fixed-dose combination of pramipexole (dopamine agonist) and ondansetron (antiemetic), currently in Phase IIb, with plans for Phase III next year [4][6] - **ALTO-101**: Targets cognitive impairment in schizophrenia, with no current approved treatments available [12][13] - **ALTO-300**: An adjunctive treatment for depression using agomelatine, with Phase IIb results expected this year [4][49] ALTO-207 Highlights - **Mechanism**: Combines pramipexole, which is effective for treatment-resistant depression (TRD), with ondansetron to mitigate side effects [6][8] - **Clinical Data**: The PAXD study showed a Cohen's d of almost 0.9, indicating significant efficacy in TRD patients [7] - **Safety and Tolerability**: 20% of patients discontinued due to nausea, highlighting the need for improved tolerability [8][26] - **Commercial Strategy**: Aiming to position ALTO-207 as a widely used adjunctive treatment, potentially expanding to monotherapy in the future [25][26] ALTO-101 Highlights - **Target**: Cognitive impairment in schizophrenia, a significant unmet need affecting 0.5%-1% of the global population [12][13] - **Mechanism**: Utilizes a PDE4 inhibitor to enhance neuroplasticity and cognition [13][14] - **Trial Design**: A crossover design with EEG as the primary outcome, focusing on circuit engagement and cognitive improvement [14][45] ALTO-300 Highlights - **Mechanism**: Agomelatine acts as a melatonergic agonist and 5-HT2C antagonist, differing from traditional antidepressants [49] - **Biomarker Use**: Employs an EEG biomarker for patient selection, aiming to enhance treatment efficacy [50] Key Insights and Future Directions - **Patient Selection**: Emphasis on biomarker-defined populations to improve trial outcomes and treatment efficacy [18][20] - **Regulatory Strategy**: Plans for a 505(b)(2) submission strategy, leveraging existing data for faster approval [12][43] - **Intellectual Property**: Strong IP portfolio extending into the mid-2040s, covering co-formulations and treatment methods [43] Additional Considerations - **Real-World Data**: Challenges in achieving effective dosing of pramipexole in clinical practice, with many patients unable to reach effective doses [27][28] - **Innovative EEG Use**: Potential for at-home EEG monitoring to facilitate patient selection and treatment monitoring [52] This summary encapsulates the key points discussed during the conference call, focusing on the company's strategic direction, product pipeline, and the innovative approaches being taken to address significant mental health challenges.

Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] - The company aims to redefine psychiatry by leveraging neurobiology to create personalized and effective treatment options [1] Upcoming Investor Conferences - Alto Neuroscience will participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 pm EST [1] - The company will also attend the Jefferies 2026 Biotech on the Beach Summit on March 10-11, 2026, focusing on one-on-one investor meetings [1] - Presentations will be accessible via a live webcast on Alto's investor relations website, with replays available afterward [1] Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] - The company’s clinical-stage pipeline includes novel drug candidates for depression, schizophrenia, and other mental health conditions [1] Intellectual Property - Alto Neuroscience has strengthened its intellectual property portfolio with the issuance of U.S. Patent Number 12,521,374, which covers methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron [1] - This patent protects the use of ondansetron to mitigate side effects related to pramipexole in the treatment of depression [1]

Core Viewpoint - Alto Neuroscience has announced the issuance of U.S. Patent Number 12,521,374 for ALTO-207, a novel treatment for depression that combines pramipexole and ondansetron, aimed at enhancing the efficacy of pramipexole while mitigating its side effects [1][2][3] Group 1: Patent and Intellectual Property - The newly issued patent protects the method of using ondansetron to reduce pramipexole-related side effects, allowing for higher doses to achieve antidepressant benefits [1] - The patent issuance strengthens the intellectual property portfolio of ALTO-207, which is expected to provide protection extending into the mid-2040s, enhancing the long-term commercial opportunity for the program [2][3] Group 2: Product Overview - ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring agonist, and ondansetron, an antiemetic, designed to enable rapid titration and higher dosing by mitigating adverse events associated with pramipexole [4] - The product is being developed to address the significant unmet need for patients with treatment-resistant depression [4] Group 3: Clinical Trial Results - In a Phase 2a clinical trial involving 32 patients, ALTO-207 met primary and secondary endpoints, showing significantly greater improvements on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [5] - Patients receiving ALTO-207 reached a mean dose of 4.1 mg per day, with an adverse event rate similar to that of the placebo group, indicating good tolerability [5] Group 4: Company Mission and Strategy - Alto Neuroscience aims to redefine psychiatry by developing personalized and effective treatment options, leveraging neurobiology and a Precision Psychiatry Platform that analyzes various brain biomarkers [6] - The company is focused on building a portfolio of differentiated, innovative, precision-driven assets protected by robust intellectual property [3]

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]

Core Insights - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders [2][8] - The company will participate in upcoming investor conferences, providing opportunities for management to present and engage with investors [1][4] Company Overview - Alto Neuroscience aims to redefine psychiatry by utilizing neurobiology to create personalized treatment options [2] - The company's Precision Psychiatry Platform™ analyzes various brain biomarkers to identify patients likely to respond to its product candidates [2] Recent Developments - Alto Neuroscience announced a $50 million private placement financing to support the development of its drug candidates, including ALTO-207 for treatment-resistant depression [7][8] - The FDA granted Fast Track designation to ALTO-101 for treating cognitive impairment associated with schizophrenia, highlighting the urgency and potential of this treatment [9] Investor Engagement - Upcoming presentations include participation in the Stifel 2025 Healthcare Conference and the Jefferies London Healthcare Conference, allowing for direct interaction with investors [4] - Presentations will be accessible via live webcast, with replays available on the company's investor relations website [1][3]

Summary of Alto Neuroscience FY Conference Call Company Overview - **Company**: Alto Neuroscience (NYSE: ANRO) - **Focus**: Precision psychiatry and biomarkers in neuropsychiatry, particularly in cognitive impairment and treatment-resistant depression [1][2] Key Points and Arguments Biomarker Selection and Research Approach - Alto emphasizes a dual approach to biomarker selection: understanding the biology of disorders and utilizing machine learning for predictive analysis [2][3] - The company prioritizes prospective replication of findings to ensure confidence in advancing drug development [3] FDA Guidelines and Regulatory Framework - Alto follows FDA's 2019 enrichment guidelines, which allow for the inclusion of biomarkers in clinical trials to enhance predictive value and reliability [6][7] - The Chief Medical Officer's experience with the FDA supports Alto's strategic alignment with regulatory expectations [7] Pipeline Overview - **ALTO-101**: A PDE4 inhibitor targeting cognitive impairment associated with schizophrenia (CIAS). Expected to read out results in the coming months [9][42] - **ALTO-207**: A combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The mechanism targets dopamine receptors, particularly the D3 subtype, to enhance efficacy while mitigating side effects [10][13][15] - **ALTO-300**: An adjunctive treatment for major depressive disorder (MDD) using agomelatine, with a focus on improving tolerability and efficacy [11][49] Clinical Efficacy and Data Insights - ALTO-207 has shown promising effect sizes in previous studies, with a Cohen's D of 0.9 indicating significant efficacy in TRD populations [14][24] - The EEG biomarker linked to ALTO-207 correlates with motivational deficits and anhedonia, providing insights into treatment response [19][20] Safety and Tolerability - The combination therapy of pramipexole and ondansetron aims to reduce nausea and vomiting, common side effects of pramipexole alone [15][29] - Monitoring for impulse control disorders is crucial, especially given pramipexole's history in Parkinson's patients [30][31] Study Design and Future Plans - Phase IIB trials for ALTO-207 are set to begin in the first half of the next year, with a robust design aimed at regulatory submission [35][36] - The ALTO-300 study is being upsized based on interim analysis findings, with a focus on rigorous patient screening and data integrity [49][50] Additional Important Insights - The need for effective treatments in neuropsychiatry is emphasized, particularly for populations with limited options [47] - Alto's commitment to high standards in clinical trial execution reflects a broader trend in the industry towards increased rigor and reliability [50] This summary encapsulates the critical aspects of Alto Neuroscience's conference call, highlighting the company's strategic focus, pipeline developments, and commitment to advancing neuropsychiatric treatments through innovative biomarker-driven approaches.

Core Insights - HMNC Brain Health and Spruce Biosciences have initiated the Phase 2 clinical trial named TAMARIND to evaluate tildacerfont as a treatment for major depressive disorder (MDD) [2][3] - The trial aims to redefine depression treatment by targeting biological roots and utilizing a proprietary patient selection tool to identify patients likely to respond to the treatment [4][7] - Topline results from the TAMARIND trial are expected in the first half of 2026 [5] Company Overview - HMNC Brain Health is a global precision psychiatry biopharmaceutical company focused on developing personalized therapies for MDD [8] - Spruce Biosciences is a late-stage biopharmaceutical company that develops novel therapies for neurological disorders with significant unmet medical needs [8] Clinical Trial Details - The TAMARIND trial is a randomized, double-blind, placebo-controlled study involving 88 adults with MDD, selected using HMNC's proprietary patient selection tool [5] - The primary endpoint is the change in depression total scores from baseline using the Hamilton Depression Rating Scale, with secondary endpoints assessing functional impairment and overall quality of life [5] Treatment Mechanism - Tildacerfont is a selective, non-steroidal oral antagonist of the CRF1 receptor, which regulates the HPA axis and is implicated in MDD [6] - By blocking the CRF1 receptor, tildacerfont may address hyperactive CRF neurotransmission and HPA axis dysfunction in MDD patients [6] Patient Selection Tool - HMNC's investigational-stage patient selection tool uses genetic markers to identify MDD patients who are more likely to benefit from CRF1 receptor antagonism [7] - This approach aims to improve treatment efficacy and reduce costs and time by moving away from a trial-and-error treatment paradigm [7]

Summary of Alto Neuroscience (ANRO) Conference Call Company Overview - **Company**: Alto Neuroscience - **Focus**: Precision psychiatry, aiming to understand individual brain biology to guide treatment development and patient selection [4][5] Key Points and Arguments Precision Psychiatry Approach - Alto Neuroscience employs a precision psychiatry approach, focusing on understanding the biology of individual patients to improve treatment outcomes [4] - The company identifies a significant need for innovation in psychiatry, given the high prevalence of mental health issues and limited advancements [4] Biomarkers and Drug Development - All programs incorporate biomarkers to enhance patient selection and treatment efficacy [5] - The company is developing multiple phase 2B studies, utilizing biomarkers to define patient populations that will benefit from treatments [6] FDA Interaction and Regulatory Strategy - The FDA is primarily concerned with clear patient definitions and inclusion/exclusion criteria, which Alto believes can be effectively addressed through their biomarker approach [12][14] - The company has engaged with the FDA regarding their programs, indicating a supportive stance if the biomarker rationale is clear [14] Recent Acquisition - Alto recently acquired a new asset, Alto 207, a fixed-dose combination of pramipexole and ondansetron, aimed at treating treatment-resistant depression (TRD) [15][16] - The combination is designed to enhance antidepressant efficacy while minimizing side effects, allowing for faster titration [16][19] Clinical Data and Efficacy - Initial studies show promising results for the combination, with a significant effect size on MADRS scores, indicating potential for rapid effects in TRD patients [22][23] - The study demonstrated a Cohen's D of 1.1, with an eight-point difference in MADRS scores between drug and placebo at eight weeks [23] Future Plans and Trials - Phase 2B trials for Alto 207 are set to begin in the first half of next year, with results expected in 2027 [26] - The company has sufficient cash runway into 2028, allowing for multiple upcoming catalysts, including three phase 2B trials [55] Other Programs - Alto is also developing an H3 inverse agonist compound, with a focus on pharmacodynamics and cognitive benefits [34][35] - The company is exploring biomarkers for cognitive impairment in schizophrenia, specifically using EEG to measure treatment effects [47][49] Additional Important Insights - The company emphasizes the importance of selecting the right patient populations based on cognitive impairment metrics, which could enhance the efficacy of treatments [50] - Alto's strategy includes leveraging existing safety data to streamline the regulatory pathway for new drug combinations [31][32] - The potential for complementary biomarkers to improve treatment outcomes and payer acceptance is a key aspect of Alto's strategy [30] This summary encapsulates the critical insights from the conference call, highlighting Alto Neuroscience's innovative approach to psychiatric treatment and its strategic plans for future development.